Research reveals new molecular player in heart enlargement due to cardiac disease

Medical Xpress | January 30, 2019

In response to conditions such as high blood pressure and reduced blood flow to the cardiac muscle, the adult heart can drastically enlarge, a process called pathological hypertrophy that preserves cardiac function in the short term but predisposes patients to intractable heart failure and sudden cardiac death if left untreated. Now, researchers at the University of North Carolina School of Medicine found that the RNA-binding protein Lin28a is needed for the development of pathological hypertrophy. Published in the journal Circulation, the discovery could have a considerable impact on the development of more potent therapeutics for the treatment of heart disease, the leading cause of death in the United States and around the world.
"One of the initial steps of gene regulation is the transcription of a DNA sequence into RNA. However, post-transcriptional regulation, by RNA-binding proteins has emerged as a critical regulatory layer for the control of gene function in health and disease," said Jiandong Liu, Ph.D., associate professor of pathology and laboratory medicine at UNC and the study's senior author. During pathological hypertrophy, the heart undergoes extensive structural changes that are known to involve profound alterations in cardiac gene expression.

Spotlight

Bolstered with a successful launch in Germany and the UK of its anemia treatment Feraccru, Shield Therapeutics is looking to expand both the label and its market reach. Co-Founder and CEO Carl Sterritt reveals to Mike Ward, Informa Pharma Intelligence’s insights global director of content, his ambitions to build a West European and US-focused specialty pharma while seeking in-country specialists to partner other markets.

Spotlight

Bolstered with a successful launch in Germany and the UK of its anemia treatment Feraccru, Shield Therapeutics is looking to expand both the label and its market reach. Co-Founder and CEO Carl Sterritt reveals to Mike Ward, Informa Pharma Intelligence’s insights global director of content, his ambitions to build a West European and US-focused specialty pharma while seeking in-country specialists to partner other markets.

Related News

CELL AND GENE THERAPY

ElevateBio Announces Issuance of U.S. Patent Providing Protection for RNA-Guided Nucleases Identified through its Life Edit Gene Editing Platform

ElevateBio | November 25, 2021

ElevateBio, LLC, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced that the United States Patent and Trademark Office has issued US Patent No. 11,162,114 with an anticipated expiry date of June 23, 2040, inclusive of 384 days of patent term adjustment . This patent, issued to LifeEDIT Therapeutics, Inc. is the first to provide composition and methods of use protection for various RNA-guided nucleases in Life Edit’s gene editing platform. Life Edit is an ElevateBio company and holds an array of novel RGNs and base editors. "This patent issuance marks an important milestone for the Life Edit gene editing platform and is an acknowledgement of the uniqueness of our powerful suite of editing systems. ElevateBio will continue to build and strengthen our portfolio of patents surrounding our enabling platforms, which also include iPSCs, viral vector, and cell and protein engineering, that offer critical technologies and capabilities to facilitate the development of next-generation cell and gene therapies.” Mitchell Finer, Ph.D., President, R&D of ElevateBio and Chief Executive Officer of Life Edit This patent is directed to compositions of polynucleotides encoding various RGN polypeptides, CRISPR systems comprising guide RNAs and such RGN polypeptides, as well as methods for binding, cleaving and modifying a target DNA sequence of interest with the use of these novel RGNs and one or more guide RNAs. About ElevateBio ElevateBio is a cell and gene therapy technology company designed to power the development and manufacturing of transformative cell and gene therapies. ElevateBio has assembled industry-leading talent, built world-class facilities, and integrated diverse technology platforms necessary to drive innovation and commercialization of cell, gene, and regenerative therapies. ElevateBio has built an initial technology stack, including gene editing, induced pluripotent stem cells, and protein, viral, and cellular engineering, that can be leveraged across the entire portfolio and by strategic partners. At the center of the business model is ElevateBio BaseCamp, a centralized research and development and manufacturing company that offers R&D, process development, and Current Good Manufacturing Practice manufacturing capabilities. ElevateBio is focused on increasing long-term collaborations with industry partners while also developing its own highly innovative cell and gene therapies. ElevateBio's team of scientists, drug developers, and company builders are redefining what it means to be a technology company in the world of drug development, blurring the line between technology and healthcare.

Read More

RESEARCH

Abveris Announces Multi-Target, Multi-Year Therapeutic Antibody Discovery Collaboration with Prometheus Biosciences

Abveris, Biosciences | November 12, 2021

Abveris, a leader in antibody drug discovery announced that Prometheus Biosciences and Abveris have entered a multi-year collaboration to develop therapeutic antibodies against multiple targets. The partnership will expand Abveris's role in supporting the rapid development of the Prometheus Biosciences portfolio. The results of the collaboration will bring promising new therapeutics to patients suffering from a variety of immune-mediated diseases. Under this partnership agreement, Abveris will utilize its proprietary DiversimAbTM hyperimmune mouse technology in combination with humanized mice to develop antibodies against several novel therapeutic targets. Capitalizing on the use of its industry-leading rapid B cell screening platform powered by the Berkeley Lights Beacon®, Abveris will identify promising antibody drug candidates via function-forward, high-resolution screening under expedited timelines. "We are proud to expand our existing partnership with the team at Prometheus Biosciences to help bring novel biologics to the autoimmune spaceThe Abveris antibody discovery platform, combined with the drug development capabilities of the Prometheus team, will provide promising therapeutics to patients around the world." Tracey Mullen, Chief Executive Officer at Abveris "Our team has been impressed by Abveris' exceptional level of scientific expertise and ability to discover and deliver antibodies with potential to translate into therapeutic candidates" said Olivier Laurent, Ph.D., Chief Technology Officer of Prometheus. "We look forward to continuing our partnership with Abveris to aid in our portfolio expansion with the common goal of bringing transformational therapies to patients." About Prometheus Biosciences Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bowel disease (IBD). The Company's precision medicine platform, Prometheus360, combines proprietary machine learning-based analytical approaches with one of the world's largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. The Company's lead candidate, PRA023, is an IgG1 humanized monoclonal antibody (mAb) for the treatment of the two most common forms of IBD, Ulcerative Colitis (UC) and Crohn's Disease (CD). The Company has initiated enrollment in a Phase 2 trial in UC patients and a Phase 2a trial in CD patients, each utilizing a genetic-based companion diagnostic designed to identify patients more likely to respond to PRA023. About Abveris Abveris is Boston's premier antibody discovery company providing contract research services to the biopharma industry. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services. Abveris is developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global biopharma leaders.

Read More

CELL AND GENE THERAPY

Vizgen Releases Commercial MERSCOPE Platform

Vizgen | August 31, 2021

Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced shipment of the first commercial MERSCOPETM Platforms, marking the successful start of their limited summer release program. These first platforms are being purchased by leading research institutes including the Salk Institute, the University of California, Irvine, and the Beth Israel Deaconess Medical Center. Vizgen will continue shipping a limited number of commercial instruments for the next several months before releasing MERSCOPE to the U.S. market at large in late 2021. MERSCOPE is the first commercially available high-plex single-cell spatial genomics platform, and the only platform for MERFISH technology. Developed in the laboratory of Dr. Xiaowei Zhuang, a Howard Hughes Medical Institute Investigator, and David B. Arnold, Jr. Professor of Science at Harvard University, MERFISH provides the highest detection efficiency available for spatially profiling gene expression across whole tissues and resolving individual transcripts with nanometer-scale resolution through combinatorial labeling, sequential imaging, and error-robust barcoding. “This is a revolutionary time for the field of genomics. Researchers across the country are now able to access the spatial dimension to answer new kinds of scientific questions and make significant biological discoveries,” said Terry Lo, President and CEO of Vizgen. “Profiling the expression of hundreds of genes, in hundreds of thousands of cells, for hundreds of millions of transcripts all while retaining the spatial information within the tissue architecture has never been done before. What was previously unimaginable, MERSCOPE now makes routine.” About Vizgen Vizgen is dedicated to pioneering the next generation of genomics, providing tools that demonstrate the possibilities of in situ single cell spatial genomics, setting the standard for the spatial genomics field. These tools are enabling researchers to gain new insight into the biological systems that govern human health and disease with spatial context. The company's MERSCOPETM platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. MERSCOPE provides transformative insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, cell and gene therapy, and is an essential tool for accelerating drug discovery and development.

Read More